Atezolizumab inhibits proliferation and induces immune independent apoptosis of osteosarcoma cells. The proliferation of HOS and 143B both were inhibited by atezolizumab in a dose-dependent manner. The IC50 values of HOS and 143B were between 10-20 μg/ml. Atezolizumab treatment reduces endotoxin levels and intestinal mucosal permeability as well as decreases ileum histological scores in septic mice. However, atezolizumab treatment increases the expression of tight junction proteins in the ileum during sepsis.
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
Atezolizumab is an FDA-approved targeted therapy drug. It is a monoclonal antibody that works by binding to PD-L1, a protein on the surface of certain cancer cells, thus preventing the cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells. Atezolizumab is approved for use alone or with other drugs to treat Alveolar soft part sarcoma, Hepatocellular carcinoma, Melanoma, Non-small cell lung cancer and Small cell lung cancer.
